抵克力得预防重组人类促红细胞生成素诱发顽固性高血压和血栓症的临床研究  

The Clinic Study of Ticlopidine for Prevention Hypertension and Thrombosis Induced by Recombinant Human Erythropoietin

作　　者：李国贤[1] 周丽华[1] 黄秀美[1] 罗国惠 

机构地区：[1]厦门市中山医院血透室,361004

出　　处：《血栓与止血学》1995年第2期49-51,95,共4页Chinese Journal of Thrombosis and Hemostasis

摘　　要：用抵克力得预防重组人类促红细胞生成素(rHuEPO)治疗尿毒症的血栓并发症共17例。并讨论其机理。证实药品改善了血小板聚集功能,能使rHuEPO导致的高血压与血栓症的不良作用得到改善。The effect of Ticlopidin on 17 cases of uremic patients received rHuEPO treatment was observed. The pathogenesis of hypertension and thombosis induced by rHuE-PO was discussed in this paper. The observation prove hat changes in platelet aggregability induced by rHuEPO may be involved in the pathogenesis of hypertension and thrombosis induced by this hormone and ticJopidine may effectively inhibit this pathogenesis and prevent hypertension and thrombosis induced by rHuEPO.

关 键 词：抵克力得 重组人类促红细胞生成索 高血压 血栓症 

分 类 号：R544.1[医药卫生—心血管疾病]